Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma

Clinical Cancer Research

Volumn 22, Issue 22, 2016, Pages 5461-5471

  Choueiri, Toni K ^a   Fishman, Mayer N ^b   Escudier, Bernard ^c   McDermott, David F ^d   Drake, Charles G ^e   Kluger, Harriet ^f   Stadler, Walter M ^g   Perez Gracia, Jose Luis ^h   McNeel, Douglas G ⁱ   Curti, Brendan ^j   Harrison, Michael R ^k   Plimack, Elizabeth R ^l   Appleman, Leonard ^m   Fong, Lawrence ⁿ   Albiges, Laurence ^c,o   Cohen, Lewis ^p   Young, Tina C ^p   Chasalow, Scott D ^p   Ross Macdonald, Petra ^p   Srivastava, Shivani ^p   Jure Kunkel, Maria ^p   Kurland, John F ^p   Simon, Jason S ^p,q,r   Sznol, Mario ^p   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f YALE CANCER CENTER   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h UNIVERSITY CLINIC OF NAVARRA   (Spain)

ⁱ UNIVERSITY OF WISCONSIN   (United States)

^j EARLE A CHILES RESEARCH INSTITUTE   (United States)

^k DUKE UNIVERSITY MEDICAL CENTER   (United States)

^l FOX CHASE CANCER CENTER   (United States)

^m UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o DANA FARBER CANCER INSTITUTE   (United States)

^p BRISTOL MYERS SQUIBB   (United States)

^q JOHNSON AND JOHNSON   (United States)

^r ASTRAZENECA   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; EVEROLIMUS; GAMMA INTERFERON; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; CANCER INHIBITION; CONFERENCE PAPER; CONTROLLED STUDY; CXCL9 GENE; DISEASE ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION; CLINICAL TRIAL; DRUG EFFECTS; IMMUNOLOGY; KIDNEY TUMOR; LYMPHOCYTE; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PROSPECTIVE STUDY; RENAL CELL CARCINOMA; TUMOR MICROENVIRONMENT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; B7-H1 ANTIGEN; CARCINOMA, RENAL CELL; CHEMOKINE CXCL10; CHEMOKINE CXCL9; EVEROLIMUS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-GAMMA; KIDNEY NEOPLASMS; LYMPHOCYTES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TUMOR MICROENVIRONMENT; UP-REGULATION;

EID: 84995919524     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2839     Document Type: Conference Paper

References (41)

1. Buti S, Bersanelli M, Sikokis A, Maines F, Facchinetti F, Bria E, et al. Chemotherapy in metastatic renal cell carcinoma today? A systematic review. Anticancer Drugs 2013;24:535-54.
2. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13:688-96.
3. Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2014;32:760-7.
4. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116:4256-65.
5. Motzer RJ, Porta C, Vogelzang NJ, Sternberg CN, Szczylik C, Zolnierek J, et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:286-96.
6. Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013;14:552-62.
7. Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2014; 11:24-37.
8. Harshman LC, Drake CG, Choueiri TK. PD-1 blockade in renal cell carcinoma: to equilibrium and beyond. Cancer Immunol Res 2014;2: 1132-41.
9. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
10. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-75.
11. Drake CG, McDermott DF, Sznol M, Choueiri TK, Kluger HM, Powderly JD, et al. Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up. J Clin Oncol 2013;31(suppl). Abstr nr 4514.
12. Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 2014;33:1430-7.
13. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
14. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020-30.
15. McDermott DF, Drake CG, Sznol M, Choueiri TK, Powderly JD, Smith DC, et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol 2015;33:2013-20.
16. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1803-13.
17. Hernandez-Yanez M, Heymach JV, Zurita AJ. Circulating biomarkers in advanced renal cell carcinoma: clinical applications. Curr Oncol Rep 2012;14:221-9.
18. Gajewski TF, Louahed J, Brichard VG. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J 2010;16:399-403.
19. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013;14:1014-22.
20. Camisaschi C, Vallacchi V, Castelli C, Rivoltini L, Rodolfo M. Immune cells in the melanoma microenvironment hold information for prediction of the risk of recurrence and response to treatment. Expert Rev Mol Diagn 2014;14:643-6.
21. Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2012;61:1019-31.
22. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-71.
23. Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 2010;16:2861-71.
24. Bedognetti D, Spivey TL, Zhao Y, Uccellini L, Tomei S, Dudley ME, et al. CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. Br J Cancer 2013;109:2412-23.
25. Sznol M, Kluger HM, Callahan MK, Postow MA, Gordon RA, Segel NH, et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). J Clin Oncol 2014;32(suppl). Abstr nr LBA9003.
26. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix Gene Chip probe level data. Nucleic Acids Res 2003;31:e15.
27. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, et al. Evolving gene/transcript definitions significantly alter the interpretation of Gene Chip data. Nucleic Acids Res 2005;33:e175.
28. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc.htm#ctc-40 Last Updated: March 3, 2016.
29. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934;26:404-13.
30. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 1982;38:29-41.
31. Pinheiro J, Bates D, Deb Roy S, Sarkar D, the R Development Core Team. Linear and non-linear mixed effects model. R package version 3.1-109. 2-20-2013.
32. Tilford CA, Siemer NO. Gene set enrichment analysis. In: Nikolsky Y, Bryant J editors. Protein networks and pathways. New York, NY: Humana Press; 2009. p. 99-122.
33. Abbas AR, Baldwin D, Ma Y, Ouyang W, Gurney A, Martin F, et al. Immune response in silico (IRIS): immune-specific genes identified from a compendium of microarray expression data. Genes Immun 2005;6: 319-31.
34. Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, Baldwin N, et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 2008;29:150-64.
35. Kondo T, Nakazawa H, Ito F, Hashimoto Y, Osaka Y, Futatsuyama K, et al. Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1-type immune response. Cancer Sci 2006;97:780-6.
36. Dowlati A, Haaga J, Remick SC, Spiro TP, Gerson SL, Liu L, et al. Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. Clin Cancer Res 2001;7:2971-6.
37. Gasperini S, Marchi M, Calzetti F, Laudanna C, Vicentini L, Olsen H, et al. Gene expression and production of the monokine induced by IFN-gamma (MIG), IFN-inducible T cell alpha chemoattractant (I-TAC), and IFNgamma-inducible protein-10 (IP-10) chemokines by human neutrophils. J Immunol 1999;162:4928-37.
38. Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 2003; 170:1257-66.
39. Rodig N, Ryan T, Allen JA, Pang H, Grabie N, Chernova T, et al. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+T cell activation and cytolysis. Eur J Immunol 2003;33:3117-26.
40. Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res 2012;72:5209-18.
41. Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol 2015;194:950-9.